FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

Agile NDA Resubmitted for Contraceptive Patch

FDA accepts for review an Agile Therapeutics NDA resubmission for Twirla (ethinyl estradiol and levonorgestrel transdermal system), an investigational...

Medical Devices

FDA Wants Software Precertification Test Cases

FDA says it is looking for volunteers from a broad spectrum of software developers to provide test cases for the software as a medical device precerti...

Human Drugs

FDA Consumer Health Activities Updated

FDA chief of staff Lauren Silvis says the agency continues to urge congressional reform of the OTC monograph system to encourage more innovation.

Human Drugs

EpiBone IND OKd for Stem Cell Bone Defect Study

FDA approves an EpiBone IND to allow a Phase 1/2 clinical trial of its lead bone product, EpiBone-Craniomaxillofacial, that is being evaluated as a po...

Human Drugs

Court Closes Pharm D Solutions Drug Compounder

A Texas federal judge approves an injunction closing the Pharm D Solutions drug compounder until it complies with federal law and other requirements.

Human Drugs

FDA Approves Expanded Use for Maynes Sorilux

FDA approves a Mayne Pharma supplemental NDA for Sorilux (calcipotriene) Foam, 0.005% to expand its use in adolescents (aged 12 years and older) with ...

Medical Devices

4 Reps Introduce Faulty Device Reporting Bill

Four House Democrats introduce legislation to increase physician reporting of faulty and unsafe medical devices.

FDA General

House Appropriation Draft Gives FDA $167 Million Boost

The House Appropriations Committee posts a draft fiscal year (FY) 2020 spending bill that would provide $5.85 billion for FDA $167 million more than ...

Medical Devices

FDA as Device Auditor and Consultant

An Exeed blog post says a new FDA regulatory approach can help the medical device industry avoid repeat violations by providing agency consultation he...

Human Drugs

CGMP Violations at Centurion Labs

FDA warns Indias Centurion Laboratories about CGMP violations in its production of finished pharmaceuticals.